Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Downgraded by ValuEngine

ValuEngine cut shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) from a hold rating to a sell rating in a report released on Monday, July 24th.

Shares of Nymox Pharmaceutical Corporation (NASDAQ NYMX) opened at 3.49 on Monday. The company’s market cap is $182.76 million. The stock’s 50 day moving average is $3.84 and its 200-day moving average is $3.83. Nymox Pharmaceutical Corporation has a one year low of $2.31 and a one year high of $5.79.

TRADEMARK VIOLATION WARNING: This news story was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.com-unik.info/2017/08/19/nymox-pharmaceutical-corporation-nasdaqnymx-lowered-to-sell-at-valuengine-updated-updated-updated.html.

In other news, Director James George Robinson purchased 54,500 shares of the business’s stock in a transaction dated Tuesday, May 30th. The shares were purchased at an average price of $3.81 per share, for a total transaction of $207,645.00. Following the completion of the purchase, the director now owns 2,957,550 shares in the company, valued at approximately $11,268,265.50. The purchase was disclosed in a document filed with the SEC, which is available at this link. In the last 90 days, insiders have bought 152,500 shares of company stock worth $583,370. Insiders own 54.00% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. bought a new stake in shares of Nymox Pharmaceutical Corporation during the second quarter worth $117,000. Rhumbline Advisers bought a new stake in shares of Nymox Pharmaceutical Corporation during the second quarter worth $134,000. Northern Trust Corp bought a new stake in shares of Nymox Pharmaceutical Corporation during the second quarter worth $199,000. Teachers Advisors LLC bought a new stake in shares of Nymox Pharmaceutical Corporation during the second quarter worth $218,000. Finally, California State Teachers Retirement System bought a new stake in shares of Nymox Pharmaceutical Corporation during the second quarter worth $222,000. Hedge funds and other institutional investors own 2.25% of the company’s stock.

Nymox Pharmaceutical Corporation Company Profile

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

What are top analysts saying about Nymox Pharmaceutical Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nymox Pharmaceutical Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit